Business Context and Reporting Period
Xencor, Inc. (XNCR) filed a Form 8-K on March 4, 2026, reporting a significant development regarding its Option and License Agreement with Alexion Pharmaceuticals, Inc. The filing addresses a dispute over royalty payments for the drug Ultomiris in the United States.
Key Financial Metrics
- Cash Position: Xencor expects to end 2026 with between $380 million and $400 million in cash, cash equivalents, and marketable debt securities.
- Liquidity Runway: Management states current resources are sufficient to fund operations and R&D into mid-2028.
- Revenue Impact: The filing does not provide current revenue, profit, or margin figures. It references a prior expectation of $100 million to $120 million in aggregate royalties through 2028, which is now in dispute.
Material Changes and Disputes
On March 2, 2026, Alexion Pharmaceuticals informed Xencor that it does not owe additional royalties for Ultomiris sales in the United States and will not make future payments under the Agreement for U.S. sales. Alexion intends to continue royalty payments for sales outside the United States. This position contradicts Xencor's December 9, 2025, announcement, which cited the issuance of U.S. Patent 12,492,253 and an expectation of receiving an estimated $100 million to $120 million in low single-digit royalties on U.S. net sales through 2028.
Outlook, Risks, and Management Commentary
Xencor disagrees with Alexion's position and is actively evaluating its options. The company has disclaimed any duty to update the statements in this report except as required by law. The primary risk identified is the potential loss of the anticipated $100 million to $120 million in royalty revenue from U.S. sales of Ultomiris.
Investor Verification Checklist
- Verify the specific legal grounds Alexion is using to dispute the royalty obligation under the Option and License Agreement.
- Monitor for updates on Xencor's legal strategy or potential litigation against Alexion.
- Confirm the status of royalty payments for Ultomiris sales outside the United States.
- Review the impact of this dispute on Xencor's 2026 and 2027 financial guidance, specifically regarding the $100 million to $120 million revenue estimate.